EGR2 and neoplasm: Downstream targets of FGF (Stat1, 3, 5, Foxo1, Etv4), GDNF (Bcl6b, Egr2, Egr3) and IGF (Igf1, Trp53, Casp8) signalling were increased in tumours, indicating pathway activation (data not shown).